Telesis bio stock.
10 Nov 2023 ... As of November 9, 2023, Telesis Bio's shares were trading at $0.681. Over the past 52 weeks, the shares have experienced a decline of 61.71%.
TBIO Telesis Bio Inc Form 8-K - Current report. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).$0.38 -0.0199 [-4.98%] Last update: 4:58PM (Delayed 15-Minutes) Get Real Time Here $0.38 0 [0.00%] Profile News Analyst Ratings Guidance Dividends Earnings Insider …Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 13: CI Telesis Bio, Inc. Provides Earnings Guidance for 2023 Nov. 13: CI Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement Nov. 0928 Jun 2023 ... The securities purchase agreement provides Telesis Bio with $28 million in initial upfront funding through the private placement of redeemable ...
Telesis Bio's stock was trading at $1.20 at the beginning of 2023. Since then, DNAY stock has decreased by 63.4% and is now trading at $0.4389. View the best ...
Codex DNA, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 5.66 million compared to USD 2.85...About Telesis Bio Telesis Bio Inc. is building biology. Creators of the BioXp® system, the world’s only fully automated gene synthesis platform, and the industry-standard Gibson Assembly® method, Telesis Bio Inc. is focused on enabling researchers with the tools they need to rapidly and securely design, code, and create synthetic DNA.
Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ...Mar 9, 2023 · Telesis Bio. SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its ... Telesis Bio Inc (NASDAQ:TBIO) showed a performance of -61.05% in past 30-days. Number of shares sold short was 0.32 million shares which calculate 14.15 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $4.00 to the stock, which implies a rise of 90.75% to its current value.Telesis Bio, Inc. (NASDAQ:DNAY) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.06. The firm earned $2.79 million during the quarter, compared to analyst estimates of $2.93 million.
May 31, 2023 · SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced ...
SAN DIEGO, Nov. 13, 2023 -- Telesis Bio Inc. , a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. “This quarter, we...
Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ...Telesis Bio Inc. stock performance at a glance Check Telesis Bio Inc.’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. TBIO Stock PerformanceIf you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...SAN DIEGO, Nov. 13, 2023 -- Telesis Bio Inc. , a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. “This quarter, we...Telesis Bio's stock was trading at $1.20 at the beginning of 2023. Since then, DNAY stock has decreased by 63.4% and is now trading at $0.4389. View the best ...SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced continued expansion of the BioXp® Select Ki t product line, releasing two novel kits to enable DNA amplification and scale-up. The BioXp® Select DNA Cloning and Amplification Kit and ...
May 31, 2023 · SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced ... Jun 22, 2022 · Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ... ReShape Lifesciences Inc stock has a Value Grade of B. Telesis Bio Inc stock has a Value Grade of A. Tivic Health Systems Inc stock has a Value Grade of B. Now that you have a bit more background about each of the 3 undervalued stocks in the Advanced Medical Equipment & Technology industry as well as their overall grades, it’s …Find the latest 89bio, Inc. (ETNB) stock quote, history, news and other vital information to help you with your stock trading and investing.SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter ...Nov 14, 2023 · Telesis Bio Inc (TBIO) has been making waves in the stock market recently, with analysts predicting a significant increase in its stock price. According to data from CNN Money, the 1 analyst offering 12-month price forecasts for TBIO has a median target of $4.00, representing a staggering 699.84% increase from the last price of $0.50. 7 Feb 2023 ... ... Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward ...
Telesis Bio Inc (TBIO) stock is up 5.4% while the S&P 500 is lower by -1.19% as of 12:48 PM on Tuesday, Mar 7. TBIO has risen $0.10 from the previous closing price of $1.85 on volume of 85,049 shares. Over the past year the S&P 500 is down -4.78% while TBIO is lower by -76.56%. TBIO lost -$1.80 per share in the over the last 12 months.
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes. The press release can be accessed via the Investor section of Telesis Bio ...About Telesis Bio Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly ® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is …About Telesis Bio Telesis Bio Inc. is building biology. Creators of the BioXp® system, the world’s only fully automated gene synthesis platform, and the industry-standard Gibson Assembly® method, Telesis Bio Inc. is focused on enabling researchers with the tools they need to rapidly and securely design, code, and create synthetic DNA. Telesis Bio Inc (NASDAQ:TBIO) showed a performance of -61.05% in past 30-days. Number of shares sold short was 0.32 million shares which calculate 14.15 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $4.00 to the stock, which implies a rise of 90.75% to its current value.A high-level overview of Talis Biomedical Corporation (TLIS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.11 Nov 2021 ... Codex DNA, fresh off raising $122 million in an initial public stock offering in June, has inked a deal to buy privately held Eton ...
Codex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Guidance SAN DIEGO - March 22, 2022 - Codex DNA, Inc. , a pioneer in...
SAN DIEGO, April 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the completion of proof-of-concept demonstrations showing that its technology can be used effectively for encoding digital data in DNA sequences, and that the information that was stored could …
Telesis Bio reflects that expansion and growth,” stated Dr. Nelson. The new name reflects the focus, strategic vision, and growth of the Company. There will be no change to corporate structure ...Nov 13, 2023 · Revenue for the September 30, 2023 year-to-date period of $20.5 million was $2.6 million, or 14.3% ahead of the prior year. Gross margin at 53.9% for the third quarter was slightly below the same period last year at 54.8% due to reduced high margin collaboration/other revenue. However, for the nine-months ended September 30, 2023, gross margin ... Telesis Bio reflects that expansion and growth,” stated Dr. Nelson. The new name reflects the focus, strategic vision, and growth of the Company. There will be no change to corporate structure ...Jun 14, 2021 · SAN DIEGO, Calif., June 14, 2021 (GLOBE NEWSWIRE) — Telesis Bio, Inc. (“Telesis Bio”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the launch of its public offering of 6.7 million shares of its common stock. The initial public offering price is ... Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? Get the ...Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents ...SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced ...SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at SynBioBeta’s Built with Biology Global Conference, which is being held in Oakland, Calif., on April 12-14, 2022. Codex DNA will be showcasing its …SAN DIEGO, Calif., June 14, 2021 (GLOBE NEWSWIRE) — Telesis Bio, Inc. (“Telesis Bio”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the launch of its public offering of 6.7 million shares of its common stock. The initial public offering price is ...13 Nov 2023 ... SAN DIEGO (AP) — SAN DIEGO (AP) — Telesis Bio, Inc. (TBIO) on Monday reported a loss of $10.6 million in its third quarter.Revenue for the September 30, 2023 year-to-date period of $20.5 million was $2.6 million, or 14.3% ahead of the prior year. Gross margin at 53.9% for the third quarter was slightly below the same period last year at 54.8% due to reduced high margin collaboration/other revenue. However, for the nine-months ended September 30, 2023, gross margin ...
Median, 31.086 M ; Mean, 665 M ; Standard Deviation, 2.375 B ; Company. AboutPricing PlansPrivacy PolicyTerms Of UseSupport ; Product. Stock ScreenerStock Ideas ...Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ...Transcript : Telesis Bio, Inc., Q1 2023 Earnings Call, May 11, 2023 May. 11: CI Telesis Bio, Inc. Appoints Eric Esser as President May. 02: CI Telesis Bio Inc. Releases Bioxp® Select Kits to Enable DNA Amplification and Scale-Up Mar. 31: CIStock Trading Strategies All; America; Europe; Asia; Our Shows Shows Strategy Must Watch Satirical Cartoon Today's Editorial Crypto Recap Stock Picks All our investments ... Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks …Instagram:https://instagram. nov stocksliberarahow to set up forex trading accountwater line and sewer insurance 13 Nov 2023 ... SAN DIEGO (AP) — SAN DIEGO (AP) — Telesis Bio, Inc. (TBIO) on Monday reported a loss of $10.6 million in its third quarter. 1979 susan b anthony worthcoinbase alternatives This month, we saw the Telesis Bio, Inc. (NASDAQ:TBIO) up an impressive 40%.But that hardly compensates for the shocking decline over the last twelve months. Specifically, the stock price nose ...13 Nov 2023 ... Less: redeemable convertible preferred stock dividends, (568, ) ; Net loss attributable to common stockholders, $, (11,199, ) ; Net loss per share ... gld stoc Nov 20, 2023 · The average price predicted for Telesis Bio Inc (TBIO) by analysts is $4.00, which is $3.63 above the current market price. The public float for TBIO is 8.76M, and at present, short sellers hold a 3.69% of that float. On November 20, 2023, the average trading volume of TBIO was 38.46K shares. Nov 27, 2023 · Telesis Bio Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Telesis Bio Inc’s trailing 12-month revenue is $31.1 million with a -128.1% profit margin. Year-over-year quarterly sales growth most recently was 52.6%. Analysts expect adjusted earnings to reach $-0.897 per share for the current fiscal ... Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 13: CI Telesis Bio, Inc. Provides Earnings Guidance for 2023 Nov. 13: CI Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement Nov. 09